Orphapacket:
  AverageAgeOfOnsets:
    AverageAgeOfOnset:
    - value: All ages
  Childs: []
  DisorderType:
    PURL: http://www.orpha.net/ORDO/Orphanet_377788
    value: Disease
  ExternalReferences:
  - ExternalReference:
      DisorderMappingRelation: 'E (Exact mapping: the two concepts are equivalent)'
      Reference: '236000'
      Source: OMIM
  - ExternalReference:
      DisorderMappingRelation: BTNT (ORPHAcode is broader than the targeted code used
        to represent it)
      Reference: '300221'
      Source: OMIM
  - ExternalReference:
      DisorderMappingRelation: BTNT (ORPHAcode is broader than the targeted code used
        to represent it)
      Reference: '400021'
      Source: OMIM
  Label: Classic Hodgkin lymphoma
  ORPHAcode: '391'
  ORPHApacketId: '391'
  PURL: http://www.orpha.net/ORDO/Orphanet_391
  Parents:
  - Parent:
    - Label: Hodgkin lymphoma
      ORPHAcode: '98293'
  - Parent:
    - Label: Epstein-Barr Virus-related cancer
      ORPHAcode: '602713'
  Phenotypes:
  - Phenotype:
      HPOFrequency: Very frequent (99-80%)
      HPOId: HP:0002665
      HPOTerm: Lymphoma
  - Phenotype:
      HPOFrequency: Very frequent (99-80%)
      HPOId: HP:0002716
      HPOTerm: Lymphadenopathy
  - Phenotype:
      HPOFrequency: Very frequent (99-80%)
      HPOId: HP:0005374
      HPOTerm: Cellular immunodeficiency
  - Phenotype:
      HPOFrequency: Very frequent (99-80%)
      HPOId: HP:0012378
      HPOTerm: Fatigue
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0000975
      HPOTerm: Hyperhidrosis
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0000989
      HPOTerm: Pruritus
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0001824
      HPOTerm: Weight loss
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0001945
      HPOTerm: Fever
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0002039
      HPOTerm: Anorexia
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0004396
      HPOTerm: Poor appetite
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0012735
      HPOTerm: Cough
  - Phenotype:
      HPOFrequency: Frequent (79-30%)
      HPOId: HP:0100749
      HPOTerm: Chest pain
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0000988
      HPOTerm: Skin rash
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0001251
      HPOTerm: Ataxia
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0001744
      HPOTerm: Splenomegaly
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0002076
      HPOTerm: Migraine
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0002093
      HPOTerm: Respiratory insufficiency
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0002105
      HPOTerm: Hemoptysis
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0002240
      HPOTerm: Hepatomegaly
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0002653
      HPOTerm: Bone pain
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0002664
      HPOTerm: Neoplasm
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0002797
      HPOTerm: Osteolysis
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0005528
      HPOTerm: Bone marrow hypocellularity
  - Phenotype:
      HPOFrequency: Occasional (29-5%)
      HPOId: HP:0009830
      HPOTerm: Peripheral neuropathy
  Prevalences:
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe [REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: France
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: Institut National du Cancer 2013[INST]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-5 / 10 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Class only
      PrevalenceType: Point prevalence
      Source: RARECARE surveillance of rare cancers in Europe 2010[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-5 / 10 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Value and class
      PrevalenceType: Lifetime Prevalence
      Source: RARECARE surveillance of rare cancers in Europe 2010[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: United States
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: National Cancer Institute 2008[INST]_emedicine[OTHER]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: China
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: emedicine[OTHER]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Japan
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: emedicine[OTHER]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Austria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Belgium
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Bulgaria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Croatia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Czech Republic
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Estonia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Finland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Germany
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Iceland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Ireland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Italy
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Latvia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Lithuania
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Malta
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Norway
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Poland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Portugal
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Slovakia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Slovenia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Spain
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Switzerland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Netherlands
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: United Kingdom
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  Synonyms:
  - Synonym: Classic Hodgkin disease
  TextSection:
    Contents: Classical Hodgkin lymphoma (CHL) is a B-cell lymphoma characterized
      histologically by the presence of large mononuclear Hodgkin cells and multinucleated
      Reed-Sternberg (HRS) cells.
    TextSectionType: Definition
  TypeOfInheritances:
    TypeOfInheritance:
    - value: Unknown
  copyright: Orphanet (c) 2023
  creationDate: '2023-12-06 11:51:54'
  version: 1.3.29 / 4.1.7 [2023-08-02] (orientdb version)
